Linezolid for the treatment of central nervous system infections in neurosurgical patients.
We report our experience with linezolid in the treatment of 5 patients with central nervous system infections subsequent to neurosurgical interventions. In all cases, initial antimicrobial treatment regimens, including a glycopeptide, either failed or were associated with significant adverse events. The good clinical outcome and the absence of significant side-effects associated with linezolid suggest that it may be an attractive alternative for the treatment of central nervous system infections, particularly in settings characterized by a high incidence of multiresistant Gram-positive pathogens.
Viale
Pierluigi
P
Clinic of Infectious and Tropical Diseases, University of Brescia, Italy. pierluigi.viale@drmm.uniud.it
Pagani
Leonardo
L
Cristini
Francesco
F
Stefini
Roberto
R
Bergomi
Riccardo
R
Colombini
Paolo
P
Carosi
Giampiero
G
D000081:Acetamides / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000601:surgery; D017809:Fatal Outcome; D006801:Humans; D007558:Italy; D000069349:Linezolid; D008875:Middle Aged; D023303:Oxazolidinones / Q000009:adverse effects / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000188:drug therapy*
D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D000069349:Linezolid